PCI in patients with previous CABG: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} {{AE}} {{Anahita}} | {{CMG}} {{AE}} {{Anahita}} | ||
==2021 ACA Revascularization Guideline== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|Class 2a Recommendation, Level of Evidence: B-R<ref name="pmid34895950">{{cite journal| author=Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM | display-authors=etal| title=2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2022 | volume= 79 | issue= 2 | pages= e21-e129 | pmid=34895950 | doi=10.1016/j.jacc.2021.09.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34895950 }} </ref> | |||
|- | |||
| bgcolor="LightGreen"|Usage of an [[Embolism|embolic]] protection device, when technically feasible, is reasonable in order to decrease the risk of [[Embolism|distal embolization]] in [[patients]] with previous [[CABG]] who are undergoing [[PCI]] of a [[saphenous vein graft]]. | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:yellow"|Class 2a Recommendation, Level of Evidence: B-NR <ref name="pmid34895950">{{cite journal| author=Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM | display-authors=etal| title=2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2022 | volume= 79 | issue= 2 | pages= e21-e129 | pmid=34895950 | doi=10.1016/j.jacc.2021.09.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34895950 }} </ref> | |||
|- | |||
| bgcolor="yellow"|If feasible, [[PCI]] of the native [[coronary artery]] is preferred over the [[PCI]] of a severely [[disease|diseased]] [[saphenous vein graft]] in [[patients]] with previous [[CABG]]. | |||
|} | |||
Revision as of 18:41, 25 June 2022
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
2021 ACA Revascularization Guideline
Class 2a Recommendation, Level of Evidence: B-R[1] |
Usage of an embolic protection device, when technically feasible, is reasonable in order to decrease the risk of distal embolization in patients with previous CABG who are undergoing PCI of a saphenous vein graft. |
Class 2a Recommendation, Level of Evidence: B-NR [1] |
If feasible, PCI of the native coronary artery is preferred over the PCI of a severely diseased saphenous vein graft in patients with previous CABG. |
References
- ↑ 1.0 1.1 Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM; et al. (2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006. PMID 34895950 Check
|pmid=
value (help).